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The viral infectivity factor gene (vif) of HIV-1 increases the infectivity of viral particles by inactivation of cellular anti-viral factors, and
supports productive viral replication in primary human CD4 T cells and in certain non-permissive T cell lines. Here, we demonstrate that Vif also
contributes to the arrest of HIV-1 infected cells in the G2 phase of the cell cycle. Viruses deleted in Vif or Vpr induce less cell cycle arrest than
wild-type virus, while cells infected with HIV-1 deleted in both Vif and Vpr have a cell cycle profile equivalent to that of uninfected cells.
Furthermore, expression of Vif alone induces accumulation of cells in the G2 phase of the cell cycle. These data demonstrate a novel role for Vif in
cell cycle regulation and suggest that Vif and Vpr independently drive G2 arrest in HIV-1 infected cells. Our results may have implications for the
actions and interactions of key HIV-1 accessory proteins in AIDS pathogenesis.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV-1 accessory proteins; Vif; Vpr; Cell cycle; T cellsIntroduction
Retroviruses depend upon host cell resources for replication.
Access to those resources may be limited to a particular phase of
the cell cycle. HIV-1 gene expression causes cell cycle arrest in
the G2 phase of the cell cycle in a wide variety of cells, from
primary human T cells to yeast (Bartz et al., 1996; Elder et al.,
2001; Gummuluru and Emerman, 1999; He et al., 1995; Jowett et
al., 1995; Re et al., 1995). Viral protein R (Vpr), a highly
conserved nuclear membrane localized protein, has been
implicated in the arrest of infected cells in the G2 phase of the
cell cycle, via inhibition of activation of p34CDC2, a regulatoryAbbreviations: Env, envelope glycoprotein; PI, propidium iodide; Vif, viral
infectivity factor; Vpr, viral protein R.
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doi:10.1016/j.virol.2006.09.026kinase controlling the G2 cell cycle checkpoint (He et al., 1995;
Jowett et al., 1995; Re et al., 1995).
Like Vpr, viral infectivity factor (Vif) is a key accessory protein
encoded by HIV-1. In particular, Vif plays a critical role in HIV-1
replication in primary human CD4 T cells (Madani and Kabat,
1998; Sheehy et al., 2002; Simon et al., 1995, 1998). Vif inhibits
the incorporation of the host innate restriction factors, APOBEC3G
and APOBEC3F, into HIV-1 virions by direct binding to
APOBEC3G/F, and induction of rapid degradation via the
ubiquitin–proteasomal pathway (Kao et al., 2003a, 2003b;
Liddament et al., 2004; Liu et al., 2004, 2005; Marin et al., 2003;
Mehle et al., 2004; Sheehy et al., 2003;Wiegand et al., 2004; Yu et
al., 2003, 2004; Zheng et al., 2004). Accordingly, Vif prevents
editing and degradation of newly synthesized HIV-1 reverse
transcripts in infected primary CD4 T cells (Kao et al., 2003a,
2003b; Mariani et al., 2003).
While one study using pseudotyped HIV-1 deleted in Vpr
showed a near complete abrogation of G2 arrest in infected cells
(Bartz et al., 1996), another study using wild-type HIV-1 with a vpr
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et al., 1995).Wewished to determine if other gene products encoded
byHIV-1 contribute to the cell cycle arrest of infected cells.Here,we
report that Vif accounts for most, if not all, of the residual cell cycle
arrest observed in T cells infected with Vpr deletion mutants.
Results
Deletion of either Vif or Vpr from the HIV-1 NLΔEnv subclone
decreases the G2:G1 ratio of transfected T cells
To determine the effect of specific viral gene products on the
cell cycle arrest observed in HIV-1 expressing cells, Jurkat TFig. 1. Deletion of either Vif or Vpr from the HIV-1 NLΔEnv subclone decreases the
DNA as described in Materials and methods. Shown here are the three mutations
NLΔEnvΔVif, and NLΔEnvΔVprΔVif). (B) Jurkat T cells were transfected with vira
mock transfected. Three days later, cells transfected with the viral deletion mutants or C
or CD8α, respectively. At this time point, approximately 10% of cells were Gag- or C
G2:G1 ratios were calculated for mock transfected cells, and for Gag- or CD8α-po
determined using bothModFitLT (not shown) and CellQuest analysis (Supplementary
a minimum of 2000 Gag+ cells per sample, and the interpretation of the data was t
statistically significant reduction in the G2:G1 ratio compared to NLΔEnv are shown. E
and 29 replicates, from 18 independent experiments, which satisfied acceptance criteria
t test was used as a post hoc test to determine significance. The differences were statcells were transfected with a series of viral deletion mutants
(Fig. 1A). The deletion of gene products from HIV-1 for these
initial studies was made in the background of an envelope
glycoprotein (Env) deletion mutant, NLΔEnv. The Envelope
gene (Env) was deleted in each case to prevent viral spread.
Viral proteins were expressed intracellularly, but infectious
virions capable of additional rounds of infection were not
produced. In this way we were able to examine the effects of
HIV-1 gene expression on the cell cycle, without the possibility
of subsequent rounds of infection.
Deletion mutants or the control vector, pCR3CD8α, were
transfected into Jurkat T cells. At 72 h post-transfection, cells
were analyzed for p24gag or CD8α expression andDNA contentG2:G1 ratio of transfected T cells. (A) Mutations were made to the HIV-1 pNL4-3
that significantly reduced the G2:G1 ratio of transfected cells (NLΔEnvΔVpr,
l deletion mutants, a CD8α expression vector (as a transfection control), or were
D8αwere stained with fluorescent antibodies specific for the viral antigen, Gag,
D8α-positive (data not shown). DNA content was determined by PI staining and
sitive cells. The cell cycle profile of the antigen-positive transfected cells was
Fig. 1), as described inMaterials andmethods. Both methods required analysis of
he same using either method. For simplicity, only those samples that showed a
ach bar represents the average±SEM (standard error of the mean) of between 14
for CellQuest analysis (described inMaterials andmethods). ADunnett (2 sided)
istically significant at the p<0.001 level (indicated by asterisks).
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calculated for each transfected cell population, to assess the
extent to which cells were arrested in the G2 phase of the cell
cycle. Cells expressing CD8α showed a slight increase in the G2:
G1 ratio, compared tomock transfected cells (Fig. 1B).While the
mechanism of this effect is not known, it is possible that
transfected cells are more likely to express protein in the G2
phase of the cell cycle. As predicted, cells expressing the viral
clone, NLΔEnv, showed an increase in G2 arrest markedly
above that of CD8α expressing control cells (Fig. 1B). Deleting
either Vif or Vpr from NLΔEnv reduced the G2:G1 ratio from
1.26±0.06 to 0.90±0.04 or 0.94±0.04, respectively. These
reductions were both highly significant (p<0.001) although,
surprisingly, virus deleted in Vpr still induced a shift from G1 to
G2. The G2:G1 ratios observed in cells transfected with Vpu,
Nef, or Tat second exon deletion mutants (1.28±0.09, 1.10±
0.10, and 1.10±0.06, respectively) were not significantly
different from the G2:G1 ratio observed in cells transfected
with intact NLΔEnv (p=1.000, p=0.585, p=0.349, respec-
tively, data not shown). Viral transfectants showing a significant
difference in G2 arrest compared to NLΔEnv are shown in Fig. 1
and indicated by an asterisk. The literature predicts that
NLΔEnvΔVpr would have less of an effect on the cell cycle
than NLΔEnv, and that is confirmed by these studies. What is
strikingly apparent from these data is that the deletion of Vif also
results in a significant decrease in cell cycle arrest.
The Vif deletion was also made in the background of
NLΔEnvΔVpr to determine whether the residual cell cycle
arrest seen with NLΔEnvΔVpr could be decreased to the
background levels seen with pCR3CD8α (see Fig. 1B).ig. 2. Deletion of either Vif or Vpr from wild-type virus, NL4-3, decreases the G2:G1 ratio of infected T cell lines. (A) Vpr is expressed in wild-type NL4-3 and NL4-
ΔVif (NLΔVif), but not in NL4-3ΔVpr (NLΔVpr) or NL4-3ΔVifΔVpr (NLΔVifΔVpr) infected cells. CEM-SS T cells were infected with mock, wild-type HIV-1
L4-3, or NL4-3 deletion mutants. Accessory gene deletions were the same as shown in Fig. 1A. Unlike in Fig. 1A, all viral DNA used to produce infectious virions for
is experiment possessed the full length Env gene. Four days after infection, cells were lysed and analyzed for expression of Vpr, Vif, Gag, and actin by Western blot.
qual amounts of protein were loaded in each lane. These data are representative of at least 5 independent experiments. (B) Representative cell cycle profiles of infected
EM-SS T cells are shown. CEM-SS T cells were infected with wild-type NL4-3, deletion mutants of NL4-3, or were mock infected. Two days later, cells were
arvested, stained for the presence of the viral antigen, Gag, and incubatedwith PI to determine DNA content. Cells modeled represent the live cells for the mock culture
nd the live, Gag+ cells for the virally infected cultures. The ModFit LT software was used to determine the cell cycle profiles depicted in the figure. The first dark peak
epresents the G1 peak. The hatched area depicts cells in the S phase of the cell cycle. The second dark peak represents cells in the G2 phase of the cell cycle. The
ercentage of cells in each phase as modeled by the ModFit LT program is shown above each peak or hatched area. The G2:G1 ratio appears in the box in the upper right
and corner of each histogram. These data are representative of 2 experiments, with 4 replicate samples. Composite data for these experiments are shown in Table 1.F
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reduced the G2:G1 ratio of transfected cells to a level that was
NOT statistically significantly different from the CD8α
transfected cells (Fig. 1B, p=0.892). Thus, deletion of both
Vif and Vpr reduced the cell cycle arrest in NLΔEnv transfected
Jurkat T cells to the level of control transfected cells, while each
deletion independently still induced G2 blockade (p<0.001).
Deletion of either Vif or Vpr from the infectious clone, NL4-3,
reduces the G2:G1 ratio of infected T cells
To confirm the results of the transfection experiments,
replication competent viruses deleted in Vif were made and
tested against wild-type and Vpr deleted viruses for their cell
cycle arrest capabilities in fully permissive CEM-SS T cells
(Fig. 2 and Table 1) and semi-permissive Jurkat T cells (data not
shown). The accessory gene deletions were identical to those
used in the transfection experiments and depicted in Fig. 1A.
However, in contrast to the transfected subclones, the replica-
tion competent viruses expressed the Env gene products
necessary for multiple rounds of infection. As shown in
Fig. 2A, Vpr is equally expressed in wild-type NL4-3 and
NLΔVif infected cells, as measured by Western blot, but is
not expressed in cells infected with HIV-1 NLΔVpr or
NLΔVprΔVif.
Two and 4 days after infection with NL4-3, NLΔVpr,
NLΔVif, or NLΔVprΔVif, CEM-SS T cells were harvested and
analyzed for p24gag expression and DNA content. Fig. 2B
displays the cell cycle profiles from a representative experiment
on day 2 post-infection and Table 1 summarizes the results of all
Table 1
Infection of CEM-SS T cells with NL4-3 deletion mutants
Cell cycle analysis
Cell
and day
Percent of cells Ratio
G1 S G2 G2:G1
Mock infected
2 44±0.74 52±1.35 5±0.64 0.11±0.01
4 46±0.65 50±1.22 5±0.77 0.10±0.02
NL4-3 infected a
2 17±0.60 32±7.13 52±7.52 3.18±0.53
4 15±1.25 34±2.38 51±3.59 3.39±0.54
NLΔVpr infected a
2 25±1.68 55±2.47 20±1.04 0.81±0.05
4 27±0.60 42±0.54 32±0.87 1.21±0.06
NLΔVif infected a
2 39±0.47 33±0.76 29±0.99 0.75±0.03
4 38±2.29 46±4.21 16±3.37 0.44±0.10
NLΔVprΔVif infected a
2 44±0.99 50±1.09 6±0.27 0.14±0.01
4 46±0.82 47±1.18 7±0.40 0.15±0.01
Percentages represent an average±SEM of 4 replicates from 2 separate
experiments.
a Only gag-positive cells were analyzed.
246 J. Wang et al. / Virology 359 (2007) 243–252experiments on days 2 or 4 post-infection. As expected, the
majority of Gag-positive NL4-3 infected cells in the culture
were arrested in the G2 phase of the cell cycle (average G2:G1
ratio>3). Deletion of Vpr (NLΔVpr) led to a decrease in G2
arrest (average G2:G1 ratios of 0.81 and 1.21 on days 2 and 4,
respectively), although, as above, a significant (p<0.05)Fig. 3. Deletion of either Vif or Vpr from wild-type virus, NL4-3, decreases the G2:G
profiles of infected PHA activated primary CD4 Tcells are shown. CD4 Tcells were p
plus IL-2. Cells were then infected with either wild-type NL4-3, deletion mutants of N
of the viral antigen, Gag, and incubated with PI for cell cycle analysis. Cells were gate
infected cultures. The ModFit LT software was used to determine the cell cycle profi
histogram. These data are representative of 3 experiments.residual shift from G1 to G2 was still seen. Interestingly, the
deletion of Vif (NLΔVif) also resulted in reduced G2 arrest of
infected cells (average G2:G1 ratios of 0.75 and 0.44). Of note,
deletion of both Vpr and Vif (NLΔVprΔVif) was required to
reduce G2 arrest to the level of mock infected cells (average G2:
G1 ratios of 0.11 and 0.10). The cell cycle profile for
NLΔVprΔVif infected cells (average G2:G1 ratios of 0.14 and
0.15) was almost identical to mock infected cells, confirming
the results of our transfection experiments. Thus, while deletion
of either Vpr or Vif reduced G2 arrest, deletion of both Vpr and
Vif was required to completely abrogate cell cycle arrest.
These observations were confirmed in NL4-3 infected PHA
activated primary human CD4 Tcells (Fig. 3). We infected PHA
activated CD4 Tcells from HIV-1-negative, healthy donors with
wild-type NL4-3 or NL4-3 deletion mutants. Two days after
infection, cells were stained with HIV-1 Gag-FITC and
propidium iodide (PI) for cell cycle analysis. As shown in
Fig. 3, G2 arrest, shown by an increased G2:G1 ratio, was
observed in wild-type NL4-3 infected cells. Deletions of either
Vif (NLΔVif) or Vpr (NLΔVpr) reduced the ratios of G2:G1
from 0.61 in NL4-3 infected cells to 0.21 in NLΔVif infected
cells, and to 0.35 in NLΔVpr infected cells. Importantly, the G2:
G1 ratio of cells infected with viruses deleted in both Vif and Vpr
(NLΔVprΔVif) was almost identical to that of mock infected
cells. These data suggest that both Vif and Vpr contribute to the
G2 arrest in HIV-1 infected primary human CD4 T cells.
Frameshift mutation of Vif from an X4-tropic virus, SG3,
dramatically reduces the G2:G1 ratio of infected T cells
In order to test whether Vif induces G2 arrest in the context
of a virus other than NL4-3, we analyzed an X4-tropic virus,1 ratio of infected PHA activated primary CD4 T cells. Representative cell cycle
urified from HIV-1-negative healthy donors and stimulated for 4 days with PHA
L4-3, or were mock infected. Two days later, cells were stained for the presence
d on live cells for the mock infected culture, and on live, Gag+ cells for the virally
les and the G2:G1 ratio appears in the box in the upper right hand corner of each
247J. Wang et al. / Virology 359 (2007) 243–252SG3, and an SG3 frameshift mutation, SG3ΔVif. Three days
after infection, CEM-SS T cells were harvested and stained with
Gag-FITC and PI to determine DNA content. Wild-type Vpr
was expressed in both SG3 and SG3ΔVif infected cells (Fig. 4A
and data not shown). The ratio of G2:G1 was dramatically
decreased from 2.39 in wild-type SG3 infected cells to 0.18 in
SG3ΔVif infected cells (Fig. 4B). Importantly, in PHA
activated primary human CD4 T cells, the G2:G1 ratios were
also markedly diminished in SG3ΔVif, compared to SG3
infected cells (0.19 versus 0.64; Fig. 4C). These data suggest
that, for certain viral isolates, Vif could be the major factor
leading to accumulation of infected cells in the G2 phase of the
cell cycle.
Expression of Vif alone is sufficient to increase the G2:G1 ratio
of uninfected cells
We reasoned that Vif might be exerting an effect on the cell
cycle via modulation of another viral protein, such as Vpr. To
test the effects of Vif expression in the absence of other viral
proteins, we co-transfected Hela cells with Vif, Vpr, or Nef
expression plasmids, and with a plasmid encoding EGFP, to
mark transfected cells. At 3 days post-transfection, cells were
analyzed for GFP and DNA content. Cells expressing Vif alone
showed a significant increase in G2 arrest, as compared to
control pcDNA (Figs. 5A and C) or Nef transfected cells (Figs.
5B and C). Consistent with previous reports, expression of Vpr
alone also induced cell cycle arrest in G2 (Figs. 5A and C;
p<0.05). These results were confirmed in CEM-SS T cells; as
shown in Fig. 6, a significant increase in the G2 arrest of EGFP+Fig. 4. Deletion of Vif from X4-tropic virus, SG3, dramatically decreases the G2:G1 ra
is expressed in both wild-type SG3 and SG3ΔVif infected CEM-SS T cells by Weste
cells (B) and PHA activated primary CD4 T cells (C) are shown. CEM-SS T cells
SG3ΔVif, or were mock infected. Three days (B) or two days (C) post-infection, cells
cell cycle analysis. Cells were gated on live cells for the mock infected culture, and on
used to determine the cell cycle profiles and the G2:G1 ratio appears in the upper righ(transfected; p<0.05), but not EGFP− (non-transfected), T cells
was induced by either Vif or Vpr. These data demonstrate that
Vif and Vpr independently contribute to the arrest of HIV-1
infected cells in the G2 phase of the cell cycle.
Discussion
Our initial experiments using transfection of Env-deleted
HIV-1 DNA suggested that Vif contributes to cell cycle arrest.
In the absence of Vpr, Vif had a significant effect on G2 arrest
in transfected cells. We pursued this observation by infecting
both semi-permissive Jurkat T cells, fully permissive CEM-SS
T cells, and PHA activated primary CD4 T cells with
replication competent virus deleted in Vif. These data provided
conclusive evidence that Vif makes a significant contribution to
the cell cycle changes induced by HIV-1. Deletion of both Vif
and Vpr from HIV-1 almost completely abrogated the ability of
the virus to induce G2 arrest. In addition, expression of Vif
alone induced an accumulation of cells in the G2 phase of the
cell cycle. These data strongly suggest that Vif, like Vpr,
contributes to HIV-1 induced G2 arrest. This finding is
consistent with a recent report showing that deletion of either
Vif or Vpr from non-replication competent virus inhibits HIV-
induced cell cycle arrest (Sakai et al., 2006).
Vif is an HIV-1 accessory protein that plays a critical role in
HIV-1 replication in primary CD4 T cells and in certain “non-
permissive” transformed T cell lines (Madani and Kabat, 1998;
Sheehy et al., 2002; Simon et al., 1995, 1998). In Vif defective
viruses, the host innate restriction factors, APOBEC3G and
APOBEC3F, are packaged into viral particles through bindingtio of infected CEM-SS T cells and PHA activated primary CD4 T cells. (A) Vpr
rn blot. (B and C) Representative cell cycle profiles of infected CEM-SS CD4 T
or PHA activated primary CD4 T cells were infected with wild-type SG3, or
were stained for the presence of the viral antigen, Gag, and incubated with PI for
the live, Gag+ cells for the virally infected cultures. The ModFit LT software was
t hand corner of each histogram. These data are representative of 3 experiments.
Fig. 5. Transfection of either Vif or Vpr increases the G2:G1 ratio of transfected Hela cells. (A and B) Hela cells were co-transfected with pcDNA3.1, Vif, Nef, or Vpr,
plus pEGFP-F. Three days post-transfection, the cells were harvested, fixed in ethanol and stained with PI to determine DNA content. The ModFit LT software was
used to determine the cell cycle profiles of the EGFP+ (transfected) cells. The G2:G1 ratio appears in the box in the upper right hand corner of each histogram. These
data are representative of 4–5 experiments performed. (C) Average±SEM of the G2:G1 ratio from 4–5 independent experiments for EGFP+ (transfected) cells are
summarized. Differences between Vpr or Vif and mock transfected cells were statistically significant, as indicated (p<0.05).
248 J. Wang et al. / Virology 359 (2007) 243–252to viral genomic RNA, leading to cytidine deamination of the
minus-strand DNA during reverse transcription, and a marked
increase in guanine (G) to adenine (A) mutations in the newly
synthesized HIV-1 reverse transcripts (Harris et al., 2003;
Mangeat et al., 2003; Zhang et al., 2003). This hypermutated
viral genome is then degraded by host cell DNA repair
enzymes. Vif counteracts the effects of APOBEC3G and
APOBEC3F, by inhibiting their incorporation into HIV-1
virions (Kao et al., 2003a, 2003b; Liddament et al., 2004; Liu
et al., 2004, 2005; Marin et al., 2003; Mariani et al., 2003;
Mehle et al., 2004; Sheehy et al., 2003; Wiegand et al., 2004; Yu
et al., 2003, 2004; Zheng et al., 2004), thereby preventing the
hypermutation and degradation of viral DNA induced by
APOBEC3G/F in target cells. While these recent discoveries
have shed considerable light on critical interactions between Vif
and host cell restriction factors, there are still unsolved
questions about the role of Vif in HIV-1 pathogenesis. For
example, Vif has been shown to bind viral genomic RNA
(Dettenhofer et al., 2000; Kao et al., 2003a, 2003b; Khan et al.,
2001; Zhang et al., 2000), where it may participate in
maintenance of correct folding and facilitate packaging andreverse transcription. Here, we show that Vif induces G2 arrest
of HIV-1 infected cells, a function previously attributed solely
to Vpr.
There is considerable evidence that Vpr induces G2 arrest in
HIV-1 infected cells (Bartz et al., 1996; Elder et al., 2001; He
et al., 1995; Jowett et al., 1995; Re et al., 1995). Cells arrested
in G2 have been shown to produce more virus (Goh et al.,
1998; Gummuluru and Emerman, 1999), although prolonged
G2 arrest ultimately leads to cell death (Stewart et al., 1997,
1999; Yuan et al., 2003). Our studies, and those of Sakai et al.
(2006), implicate Vif as another accessory protein that plays a
role in HIV-induced G2 arrest. Neither study addresses how Vif
induces G2 arrest, or why HIV-1 uses two different viral
proteins, Vpr and Vif, to arrest cells in the G2 phase of the cell
cycle. One possibility is that, since the half-life of infected cells
is short in vivo (Perelson et al., 1996), producing as much virus
as possible, in the shortest period of time, might be important
for viral propagation. Having two viral gene products
contribute to modulation of the cell cycle would seem to be
one strategy by which HIV-1 could maximize its spread.
Alternatively, Vif and Vpr may function differently under
Fig. 6. Transfection of either Vif or Vpr increases the G2:G1 ratio of transfected CEM-SS Tcells. Using nucleofection® by Amaxa, CEM-SS Tcells were co-transfected
with pcDNA3.1, Vif, or Vpr, plus pEGFP-F. Forty-eight hours after transfection, the cells were fixed in ethanol and stained with PI to determine DNA content. At this
time point, approximately 25% of cells were transfected, as determined by EGFP positivity (data not shown). ModFit LT software was used to determine the cell cycle
profiles of the EGFP+ (transfected) cells. These data are representative of 6 replicates from 3 experiments performed; the G2:G1 ratios of Vif or Vpr transfected cells
were significantly different from control (p<0.05), by the Wilcoxon signed-rank test.
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levels or stages of infection (unpublished observations), or in
the context of different viral isolates. In support of the latter,
we found that the majority of G2 arrest in wild-type SG3
infected cells was eliminated in the absence of Vif. This
suggests that, in certain viral isolates, Vif is the major viral
protein contributing to G2 arrest. It is intriguing to speculate
that Vif might target cell cycle regulatory proteins for
degradation, in a manner similar to its effects on APO-
BEC3G/F. Further study is needed to determine how (and why)
Vif, in addition to Vpr, functions to perturb the cell cycle of
HIV-1 infected cells.
Materials and methods
Cells
The leukemic T cell lines, Jurkat and CEM-SS, were
maintained in RPMI 1640 (Gibco-BRL) supplemented with
10% heat-inactivated fetal bovine serum (FBS) (Gemini
Bioproducts, Inc., Calabasas, CA), 100U/ml penicillin G+
100 μg/ml streptomycin (Gibco-BRL), and 2 mM l-glutamine
(Mediatech). The epithelioid carcinoma cell line, Hela, was
maintained in Dulbecco's minimum essential medium (Media-
tech) supplemented with 10% FBS. Primary human CD4 Tcells
were purified by RosetteSep (StemCell Technologies Inc.), and
stimulated with 1.5 μg/ml PHA and 30 U/ml IL-2 at 37 °C for
4 days. All cells were maintained at 37 °C and 5%CO2.
Plasmids
The NLΔEnv mutant (also named YK161) was described
previously (Kim and Panganiban, 1993). Briefly a StuI to NheIdeletion was made in the viral clone pNL4-3 (Adachi et al.,
1986), followed by Klenow fill-in of the overhangs. Viral
DNA's p1971-1 (5′ NLΔVif), p210-19 (5′ NLΔVpr), p210-13
(3′ NLΔVpu), p210-5 (3′ NLΔNef), and p210-25 (5′ NLΔVif
ΔVpr) were obtained from Dr. Ronald Desrosiers through the
NIH AIDS Research and Reference Reagent Program (Gibbs
et al., 1994). The mutant lacking the second exon of tat
(NLΔTSE) was described previously (Casella et al., 1999);
briefly the first codon of the second exon of tat was changed
from CAG to TAG by PCR cloning. NLΔEnvΔVpr was made
by replacing a SpeI to EcoRI fragment of NLΔEnv with the
corresponding fragment of p210-19. NLΔEnvΔVpu was made
by replacing an EcoRI to NdeI fragment of NLΔEnv with the
corresponding fragment of p210-13. NLΔEnvΔNef was made
by replacing the BamHI to BspeI fragment in NLΔEnv with
the corresponding fragment from p210-5. NLΔEnvΔTSE was
made by replacing the EcoRI to NdeI fragment in NLΔEnv
with the corresponding fragment of NLΔTSE. NLΔEnvΔVif
and NLΔEnvΔVprΔVif were made by replacing the SpeI to
EcoRI fragment of NLΔEnv with the corresponding fragments
from p1971-1 and p210-25, respectively (see Fig. 1A for
schematic representations of selected pNL4-3 deletions).
The clone, pCR3CD8α, was the kind gift of Dr. Terry Potter.
The pCR3CD8α control vector expresses mouse CD8α
containing a deleted cytoplasmic tail, under the control of the
cytomegalovirus virus immediate early promoter. pEGFP-F was
purchased from BD Biosciences Clontech (Palo Alto, CA). The
5′ tagged HA-Vpr was kindly provided by Dr. Nathaniel
Landau (He et al., 1995; DiMarzio et al., 1995). The codon-
optimized HIV-1 Vif expression plasmid was the generous gift
of Dr. Warner Greene. Briefly, in order to increase expression of
the Vif protein, the open reading frame for human codon-
optimized vif was synthesized (McLab, South San Francisco,
250 J. Wang et al. / Virology 359 (2007) 243–252CA) and cloned into the HindIII and BamHI sites of the
pcDNA3.1 Hygro(+) expression vector. The procedure fol-
lowed was substantially similar to one previously reported
(Nguyen et al., 2004) except, in this case, the entire vif gene was
human codon-optimized, increasing the GC content of vif to
55%.
Preparation of HIV-1 NL4-3 deletion mutant virus stocks
Viral DNAs, p83-2 (5′ half of NL4-3), p83-10 (3′ half of
NL4-3), p1971-1 (5′ NLΔVif), p210-19 (5′ NLΔVpr), and
p210-25 (3′ NLΔVifΔVpr) were obtained from Dr. Ronald
Desrosiers through the NIH AIDS Research and Reference
Reagent Program (Gibbs et al., 1994). Each half of the proviral
DNA (3 μg) was cut with EcoRI, ligated, and used to transfect
293 T cells using a modified calcium phosphate mediated
transfection method in BES buffer. Culture supernatants were
collected 24–48 h after transfection and used to infect CEM-SS
cells in the presence of 20 μg/ml DEAE Dextran (Sigma, St.
Louis, MO). Seven to 10 days after infection, supernatants were
clarified by centrifugation at 250×g, collected, and frozen at
−70 °C.
An aliquot from each virus preparation was tested to
ensure that the HIV-1 deletion mutant mRNA was made
during infection. CEM-SS T cells were infected with an
amount of virus similar to that used in the actual experiment.
Two days post-infection, cells were harvested and mRNA was
isolated using the Oligotex Direct mRNA Mini Kit. The
region of the isolated mRNA spanning the vif and vpr genes
was amplified by RT-PCR using the following primers: sense
primer (5′-GACATAAAAGTAGTGCCAAGA-3′); antisense
primer (5′-CTGACTTCCTGGATGCTTC-3′). The PCR pro-
ducts were sequenced, and aligned with the published
sequence (Genbank Accession numberM19921) using Blast
2 (http://www.ncbi.nlm.nih.gov/blast/). All deletions were
confirmed to be as described by Gibbs et al. (1994) and no
contamination of any of the virus preparations was noted. The
protein levels of Vif and Vpr in cells infected with NLΔVpr
or NLΔVif, respectively, were similar to those in NL4-3
infected cells (Fig. 2A and data not shown).
The HIV-1 pSG3 proviral clone contains all genes typical of
HIV-1 with the exception of vpu (Ghosh et al., 1993; Wu et al.,
1997). To generate HIV-1 SG3ΔVif, a unique Ndel site in the
vif coding sequence was digested with Ndel, filled in with
Klenow DNA polymerase, and self-ligated to generate a
frameshift mutation in Vif. The viral stocks of SG3 and
SG3ΔVif were prepared by transfecting plasmids into 293 T
cells, followed by virus amplification in CEM-SS cells. Vpr is
expressed in both wild-type SG3 and SG3ΔVif infected cells
(Fig. 6A and data not shown).
Infection by HIV-1 NL4-3 deletion mutants
Jurkat or CEM-SS cells were infected in the presence of
20 μg/ml DEAE Dextran (Sigma, St. Louis, MO), with amounts
of virus giving approximately equivalent levels of infection.
Virus was allowed to adsorb for 1–2 h at 37 °C and 5% CO2.Cells were pelleted by centrifugation, and resuspended in
growth medium at a concentration of 2×105 cells/ml for Jurkat
T cells and 3×105 cells/ml for CEM-SS T cells. Virus cultures
were maintained at 37 °C and 5% CO2.
Transfections
Jurkat T cells were transfected using Lipofectamine reagent
(GIBCO BRL, Grand Island, NY) according to the optimized
manufacturer's protocol. In some experiments, Hela cells
(2×106 cells in 10-mm culture plates) were co-transfected
using Fugene 6 (Roche Applied Science, Indianapolis, IN) with
18 μg of pcDNA, or with the Vif, Vpr, or Nef expression
plasmids, and with 2 μg of pEGFP-F. Three days after
transfection, cells were harvested, washed in PBS and then
fixed in ethanol at 4 °C. CEM-SS T cells were transfected using
nucleofection® by Amaxa (Yin et al., 2006). Approximately
2×106 cells were transfected with 1.8 μg of pcDNA, or with Vif
or Vpr expression plasmids, plus 0.2 μg of pEGFP-F in
transfection solution V (program O-17). Forty-eight hours after
transfection, cells were harvested and fixed in ethanol at 4 °C.
Cells were then washed in PBS and stained with PI (100 μg/ml
PI and 50 μg/ml RNase A in PBS) at room temperature for
60 min and kept at 4 °C until analysis by two-color flow
cytometry.
Analysis of DNA content in T cells transfected or infected with
HIV-1 deletion mutants
Transfected or infected Jurkat or CEM-SS T cells were fixed
in 1% paraformaldehyde, washed in phosphate-buffered saline
(PBS), and incubated with 2.5 μg of the KC57 FITC anti-Gag
antibody (Coulter, Hieleah, FL) in 0.1% saponin and 10% FCS
in PBS at room temperature for 30 min. The cells were washed
in PBS and incubated in PI solution (100 μg/ml PI, 0.1%
saponin, 5 mM EDTA and 50 μg/ml RNase A in PBS) for
60 min at room temperature and then kept at 4 °C until analyzed
by two-color flow cytometry. CD8α expressing cells were
stained with anti-CD8α mAb (53-6.72 FITC) for 30 min,
washed with PBS, stained with PI solution, and analyzed by
two-color flow cytometry, as described above.
ModFit LT analysis of DNA content
The ModFit LT software program (Verity Software House,
Inc., Maine, CA) was used to determine the distribution of cells
in each phase of the cell cycle (G1, S, and G2). Gates were
drawn around the live cell population, on a plot of FSC versus
SSC, and around the FL-1 (FITC or EGFP)-positive cell
population, on a plot of FL-1 versus FL-2. Acceptance criteria
for each histogram were based on the %CV, RCS, %Diploid
BAD, and cell number statistics calculated by the ModFit LT
program. %CV (coefficient of variance) directly corresponds to
the sharpness of the G1 peak and is the most important
parameter for the accuracy of the software modeling of S phase.
RCS (reverse chi squared) corresponds to the goodness of fit of
the model to the data. %Diploid BAD (Background Aggregates
251J. Wang et al. / Virology 359 (2007) 243–252and Debris) corresponds to the percentage of diploid events
modeled that may be considered aggregated cells or cellular
debris. The following limits were set: %CV<8%, RCS<6, %
Diploid BAD<20%, and cell number>2000. Exceptions were
made for histograms that did not satisfy the RCS criterion if
they satisfied all other criteria and the cell number was
excessively high (i.e.,>40,000). A higher number of cells
analyzed corresponded to higher RCS values within the same
preparation. These acceptance criteria were loosely based on
Guidelines for Clinical DNA Cytometry (Shankey et al., 1993)
and personal communications with Verity Software House.
CellQuest analysis of DNA content
The histograms obtained from ModFit LT analysis of
transfections done with the envelope deletion mutants did not
meet acceptance criteria. Therefore, we adapted a method of
analysis from Jowett et al. (1995). For each sample, a
histogram of the PI fluorescence for all cells was analyzed.
The CellQuest software program (Becton Dickinson, San Jose,
CA) was used to identify the prominent G1 peak and provide its
peak channel of fluorescence. The less visible G2 peak channel
of fluorescence was calculated to be 2 times the G1 peak
channel of fluorescence (indicating twice the DNA staining). A
midpoint between these two peak channels of fluorescence was
established and a ratio of cells appearing in channels above the
midpoint (G2 region) to cells appearing in channels below the
midpoint (G1 region) was calculated. In the text, this ratio is
referred to as the G2:G1 ratio. The S phase cells were divided
equally between the G2 region and the G1 region by this
method of analysis. As with the ModFit LT analysis, a
minimum of 2000 cells per sample were required for inclusion
in the analysis. Samples were gated to exclude debris and
aggregates and the G2:G1 ratios reported were calculated for the
FITC (p24 gag)-positive cells in HIV-1 deletion mutant
transfections and for all cells in mock transfections. The
average ratios presented in Fig. 1B were calculated in this
manner. Supplementary Fig. 1 shows the CellQuest analysis of
a representative experiment. Interestingly, the interpretation of
the data was the same whether the ModFit LT analysis or the
CellQuest analysis was used.
Flow cytometry
The cells (stained as described above) were analyzed using
the FACScan or, in some cases, the FACScalibur flow cytometer
(Becton Dickinson, San Jose, CA). When two-color analysis
was performed, electronic compensation was used to remove
spectral overlap. Twenty thousand to 100,000 events were
collected.
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